FDCC
AXNX

Foster Dykema Cabot & Co’s Axonics, Inc. Common Stock AXNX Stock Holding History

Foster Dykema Cabot & Co’s Portfolio AXNX Stock Details AXNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-77
Closed -$4K – 404
2023
Q2 		$4K Buy
+77
New +$4.1K ﹤0.01% 330

Other funds holding AXNX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Foster Dykema Cabot & Co's AXNX Position: Q3 2023 in Review

Foster Dykema Cabot & Co sold out of Axonics, Inc. Common Stock (AXNX) in Q3 2023, closing a stake of 77 shares — an estimated $4K sold.

Foster Dykema Cabot & Co first reported a position in AXNX in Q2 2023 and held it in 1 quarter. The position peaked at $4K in Q2 2023. 221 funds tracked by Wall St. Rank hold AXNX as of Q3 2023.

  • Foster Dykema Cabot & Co reported no remaining Axonics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Foster Dykema Cabot & Co sold 77 Axonics, Inc. Common Stock shares in Q3 2023, an estimated $4K.
  • Foster Dykema Cabot & Co first reported a position in Axonics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Foster Dykema Cabot & Co's Axonics, Inc. Common Stock position peaked at $4K in Q2 2023.
  • 221 funds tracked by Wall St. Rank held Axonics, Inc. Common Stock as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.